Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.35M | $-19.51M | $-0.06 |
| 2024 | $2.86M | $-14.22M | $-0.05 |
| 2023 | $2.19M | $-20.13M | $-0.08 |
| 2022 | $1.04M | $-21.69M | $-0.09 |
| 2021 | $1.01M | $-15.01M | $-0.07 |
Social Signal Score
Earnings
Thu, Apr 29(in 9 months)
Typical surprise +93.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Jun 22$-0.00 vs $-0.03beat
Estimates and results for ANPCF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ANPCFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsproactiveinvestors.co.uk·3d ago·Negative
CelLBxHealth's blood test spots hard-to-detect cells from brain tumours An independent study has found that tumour cells circulating in the blood of patients with the most aggressive form of brain cancer can be captured and analysed using technology made by CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company. Glioblastoma rarely spreads beyond the brain, which had made blood-based detection of the disease an unlikely prospect.
View source ↗